-transparent.png){kind=logo}
One hundred and eleven consecutive women with FIGO Stages III and IV ovarian adenocarcinoma were treated with melphalan as their initial chemotherapy. The response rate was 19.8% with 10.8% having a complete response. There was a statistically significant improvement in response in those women with no prior radiation therapy. Moreover, there was a statistically significant improvement in median survival in those patients achieving a complete response to melphalan as compared to those with a partial response, with no change or progression of their malignancy. A review of the results of maximal surgery and combination chemotherapy is presented as a plan of therapy to improve upon the results of melphalan chemotherapy in women with advanced ovarian carcinoma.
M S Piver, and
J J Barlow, and
R Yazigi, and
L E Blumenson
January 1977,
Cancer treatment reports,
M S Piver, and
J J Barlow, and
R Yazigi, and
L E Blumenson
November 1982,
Journal of surgical oncology,
M S Piver, and
J J Barlow, and
R Yazigi, and
L E Blumenson
July 1986,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
M S Piver, and
J J Barlow, and
R Yazigi, and
L E Blumenson
October 1986,
Tumori,
M S Piver, and
J J Barlow, and
R Yazigi, and
L E Blumenson
May 1984,
Onkologie,
M S Piver, and
J J Barlow, and
R Yazigi, and
L E Blumenson
August 2002,
Best practice & research. Clinical obstetrics & gynaecology,
M S Piver, and
J J Barlow, and
R Yazigi, and
L E Blumenson
June 1968,
Clinical obstetrics and gynecology,
M S Piver, and
J J Barlow, and
R Yazigi, and
L E Blumenson
September 1981,
American journal of obstetrics and gynecology,
M S Piver, and
J J Barlow, and
R Yazigi, and
L E Blumenson
December 1978,
The New England journal of medicine,
M S Piver, and
J J Barlow, and
R Yazigi, and
L E Blumenson
January 1984,
European journal of cancer & clinical oncology,
